Cipla Ltd

Cipla Employee Stock Options

Cipla allotted 12,168 equity shares following the exercise of options under its ESOS and ESAR schemes. This increases the company's total paid-up share capital.

Cipla Management Change

Cipla Ltd announced that Mr. Venkata Sai Mungara has transitioned to a subsidiary role, ceasing to be a Senior Management Personnel effective October 1, 2026.

Cipla Other Announcement

Cipla announced it was assigned an ESG rating of 68 by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, a SEBI-registered rating provider.

Cipla Acquisition

Cipla is notifying shareholders and creditors about a Scheme of Amalgamation with Inzpera Healthsciences, providing them an opportunity to submit representations to the NCLT.

Cipla Partnership

Cipla signed an exclusive licensing and supply agreement with SBP Group’s CTTQ for the drug Rolditamig Deuderuxtecan. This collaboration aims to accelerate therapy access in licensed markets.

Cipla Merger & Restructuring

Cipla Ltd. announced an internal restructuring where Aspergen Limited, India, acquired a 100% stake in Aspergen Inc., USA, from existing group subsidiaries.

Cipla Employee Stock Options

Cipla allotted 5,281 equity shares to employees upon exercise of options under its ESOS and ESAR schemes.

Cipla Business Update

Cipla reported receiving seven inspectional observations from the USFDA following a cGMP inspection at its Pithampur facility. The company intends to address these observations promptly.

Cipla Acquisition

Cipla Ltd announced that the NCLT has allowed the scheme application for the amalgamation of its wholly-owned subsidiary, Inzpera Healthsciences Ltd, into Cipla Ltd.

Cipla Other Announcement

Cipla Limited received updated ESG ratings from SES and NSE. SES assigned a score of 69.9 while NSE assigned 67 for the FY 2025-26 period.

Cipla Business Update

Cipla announced that its subsidiary, InvaGen, received the Establishment Inspection Report from the USFDA, officially closing the inspection of its Hauppauge facility.

Cipla Employee Stock Options

Cipla allotted 7,850 equity shares under its ESOS and ESAR schemes. This allotment increases the company's total issued and paid-up share capital.

Cipla Regulatory Approval

Cipla received U.S. FDA approval for its Generic Advair Diskus. The product is expected to launch in the U.S. market in Q2 FY 2026-27.

Cipla Earnings Call Transcript: Key Takeaways

Cipla delivered record Q1 FY27 revenue of INR 7,119 Cr with 2% reported growth (4% adjusted). Strategy focuses on U.S. respiratory launches and 'One India' chronic therapies.

Cipla Employee Stock Options

Cipla Limited granted 5,530 stock options and 19,179 Employee Stock Appreciation Rights. These grants are part of the company's 2013 and 2021 employee incentive schemes.

Cipla Management Change

Cipla has appointed Mr. Dinesh Jain as Global CFO. Mr. Ashish Aduka transitions to an internal business leadership role.

Cipla Investor Presentation: Key Takeaways

Cipla delivered record Q1 revenue of INR 7,119 Cr, driven by strong growth in India and the US. EBITDA margins stood at 16.7% with PAT at INR 789 Cr.

Cipla Results Update

Cipla reported Q1FY27 revenue of ₹7,119 Crore and PAT of ₹789 Crore. The company achieved its highest-ever quarterly revenue with 12% growth in India.

Value

₹7,119 Cr

Cipla Q1 FY27 Results: Net Profit ₹785.5 Cr, Down 39.2% YoY

Cipla Ltd reported revenue from operations of ₹7,119 Cr (+2.3% YoY) and net profit of ₹785.5 Cr (-39.2% YoY) for Q1 FY27.

Key figure

Net profit ₹785.5 Cr · -39.2% YoY

Cipla Other Announcement

Cipla Ltd has submitted its shareholding pattern for the quarter ending June 30, 2026. The filing details holdings across promoter and public categories.

Cipla Business Update

Cipla informed that a USFDA inspection at its InvaGen subsidiary in New York concluded with one Form 483 observation, which will be addressed promptly.

Cipla Other Announcement

Crisil ESG Ratings assigned Cipla an ESG score of 69 and a Core ESG score of 66. These independent ratings reflect the company's sustainability performance.

Cipla Annual General Meeting

Cipla Ltd has filed the transcript of its 90th Annual General Meeting held on June 25, 2026. The meeting was conducted via video conferencing as per statutory requirements.

Cipla Management Change

Cipla Limited appointed B S R & Co. LLP as Statutory Auditor for a five-year term. This follows the tenure completion of Walker Chandiok & Co. LLP.

Execution

60 months

Cipla Other Announcement

Cipla appointed M/s B S R & Co. LLP as statutory auditors. This follows the completion of M/s Walker Chandiok & Co. LLP's second term.

Cipla Annual General Meeting

Cipla Ltd disclosed the voting results and scrutinizer's report for its 90th AGM. Six resolutions were passed during the meeting.

Cipla Business Update

Cipla disclosed that ESG Rating Provider ESGRisks.ai revised its ESG score from 68 to 64. The update is filed under Regulation 30.

Cipla Board Meeting Date

Cipla has scheduled a board meeting for July 23, 2026. The meeting will consider unaudited financial results for the quarter ended June 30, 2026.

Cipla Business Update

USFDA classified Cipla's Verna, Goa facility inspection as Voluntary Action Indicated (VAI). This status allows continued operations while the company addresses administrative observations.

Cipla Annual Report

Cipla issued a corrigendum to its 90th AGM notice and FY 2025-26 Annual Report. The correction rectifies the remote e-voting end date to June 24, 2026.